PD16: Benign Prostatic Hyperplasia: Basic Research & Pathophysiology

Podium Session Moderator(s)

• 

  Gail Prins, PhD

  Michael Reese Professor
  University of Illinois at Chicago
• 

  Brian Helfand, MD

  University of Chicago

Presentations:

• 4:00 PM – 4:10 PM

  PD16-04: The protective effects of CSF-1R inhibition on bladder outlet obstruction (BOO) induced remodeling
  

  Podium Presenter: Wei Wang
• 4:10 PM – 4:20 PM

  PD16-05: Loss of Osteopontin improves urinary function and alters the prostatic immune environment
  

  Podium Presenter: Petra Popovics, PhD
• 4:20 PM – 4:30 PM

  PD16-06: Shift change of the activated complement pathway in the fibrotic process associated with progression of benign prostatic hyperplasia
  

  Podium Presenter: Junya Hata, MD – Fukushima Medical University
• 4:30 PM – 4:40 PM

  PD16-07: Reassessment of the effect of lower urinary tract obstruction on urothelial tissue: evaluation via HoLEP and animal study
  

  Podium Presenter: Young-min Yang
• 4:40 PM – 4:50 PM

  PD16-08: Alternate Androgen-independent Estrogen Signaling for Prostatic Growth
  

  Podium Presenter: Christina Sharkey, BS,MA – Beth Israel Deaconess Medical Center
• 4:50 PM – 5:00 PM

  PD16-09: The role of GPER signaling in development of prostatic enlargement in high fat diet induced obesity rat model
  

  Podium Presenter: Shinsuke Mizoguchi
• 5:00 PM – 5:10 PM

  PD16-10: 5-alpha reductase inhibitors suppress dihydrotestosterone in Benign Prostate Hyperplasia requiring surgery, and cause steroidogenesis via 5ARI induced pathway
  

  Podium Presenter: Connor M. Forbes, MD
• 5:10 PM – 5:20 PM

  PD16-11: Trans-ethnic genome-wide association study reveals new therapeutic targets for benign prostatic hyperplasia.
  

  Podium Presenter: Richard John Bryant, MD
• 5:20 PM – 5:30 PM

  PD16-12: Age and Race specific gene signature: An independent predictor of prostate cancer in racially diverse military cohort of African and Caucasian American patients
  

  Podium Presenter: Shashwat Sharad